FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Alberto Alvarez-Larrán

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Living Beings

Young Adult

Anatomy

Thrombosis

Physiology

Procedures

Co-author Network

Publications

TOP 3
Juan-Carlos Hernández-Boluda; Ana Kerguelen; José Antonio Márquez; Arturo Pereira; Alberto Alvarez-Larrán; María Luisa Antelo; Eduardo Arellano-Rodrigo; Carles Besses; Francisco Cervantes; Francisca Ferrer-Marín; Montse Gómez
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
Josep-María Ribera; Josep Sarrá; Mar Tormo; Alberto Alvarez-Larrán; María-Teresa Bernal; Salut Brunet; Maria Calbacho; Pascual Fernández-Abellán; Olga García; José González-Campos; Esperanza Lavilla; María-Carmen Monteserín; Pau Montesinos; Albert Oriol
Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols.
Carlos Besses; Ruth Coll; Alberto Alvarez-Larrán; Patrick Martin; Jaideep Purkayastha; Steven Troy; Wolfgang Zeller; Christian Freitag
Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Alberto Alvarez-Larrán (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Juan-Carlos Hernández-Boluda; Ana Kerguelen; José Antonio Márquez; Arturo Pereira; Alberto Alvarez-Larrán; María Luisa Antelo; Eduardo Arellano-Rodrigo; Carles Besses; Francisco Cervantes; Francisca Ferrer-Marín; Montse Gómez
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
Annals of hematology 2013;92(6):771-5.
2012: Josep-María Ribera; Josep Sarrá; Mar Tormo; Alberto Alvarez-Larrán; María-Teresa Bernal; Salut Brunet; Maria Calbacho; Pascual Fernández-Abellán; Olga García; José González-Campos; Esperanza Lavilla; María-Carmen Monteserín; Pau Montesinos; Albert Oriol
Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols.
British journal of haematology 2012;159(4):485-8.
2012: Carlos Besses; Ruth Coll; Alberto Alvarez-Larrán; Patrick Martin; Jaideep Purkayastha; Steven Troy; Wolfgang Zeller; Christian Freitag
Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 - 50 years) and elderly (≥ 65 years) patients with essential thrombocythemia.
International journal of clinical pharmacology and therapeutics 2012;50(11):787-96.
2012: Alberto Alvarez-Larrán; Agueda Ancochea; Anna Angona; Beatriz Bellosillo; Francesc García-Pallarols; Luz Martínez-Avilés; Carmen Pedro; Carles Besses
Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia.
Haematologica 2012;97(11):1704-7.
2012: Alberto Alvarez-Larrán
[Quantification of JAK2V617F mutational burden in chronic myeloproliferative neoplasms].
Medicina clínica 2012;139(9):393-4.
2012: Luz Martínez-Avilés; Gemma Navarro; Carmen Pedro; Sergi Serrano; Erica Torres; Alberto Alvarez-Larrán; Anna Angona; Carles Besses; Lourdes Florensa; Raquel Longarón; Beatriz Bellosillo
Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia.
Annals of hematology 2012;91(10):1555-62.
2012: Alberto Alvarez-Larrán; Francisco Lomeña; Jordi Rimola; María Rozman
[A 67 year-old male with abdominal pain, splenomegaly, lymphadenopathies, and bone density changes].
Medicina clínica 2012;139(7):300-6.
2012: Juan-Carlos Hernández-Boluda; Margherita Maffioli; Isabel Marugán; Arturo Pereira; Esperanza Such; Blanca Xicoy; Alberto Alvarez-Larrán; Paula Amat; M Jesús Arilla; Beatriz Bellosillo; Carles Besses; Concepción Boqué; Francisco Cervantes; María Collado; Vicente Guillem
A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera.
Blood 2012;119(22):5221-8.
2012: Luz Martínez-Avilés; Sergi Serrano; Erica Torres; Alberto Alvarez-Larrán; Carles Besses; Beatriz Bellosillo
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
Annals of hematology 2012;91(4):533-41.
2012: Alberto Alvarez-Larrán; Anna Angona; Beatriz Bellosillo; Luz Martínez-Avilés; Carlos Besses
Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Leukemia research 2012;36(3):324-6.
2012: Alberto Alvarez-Larrán; Anna Angona; Eduardo Arellano-Rodrigo; Beatriz Bellosillo; Carmen Burgaleta; Francisco Cervantes; Francisca Ferrer-Marín; Montse Gómez; Helga Guillén; Juan-Carlos Hernández-Boluda; Begoña Muiña; Arturo Pereira; Anabel Teruel; Vicente Vicente; Carles Besses
Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.
Blood 2012;119(6):1363-9.
2012: Eduardo Arellano-Rodrigo; Josep Maria Jou; Juan Carlos Reverter; Neus Villamor; Alberto Alvarez-Larrán; Francisco Cervantes
Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia.
Platelets 2012;23(5):336-43.
2011: Margherita Maffioli; Rolando Vallansot; Alberto Alvarez-Larrán; Beatriz Bellosillo; Mireia Camós; Dolors Colomer; Dolors Costa; Abel Domingo; Anna Gaya; Miquel Granell; Vicent Guillem; Juan-Carlos Hernández-Boluda; Francisco Cervantes
Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.
Leukemia research 2011;35(8):1014-9.
2011: Eva Gimeno; Miquel Gómez; Juan Ramón González; Lluis Molina; Carmen Pedro; Eugenia Abella; Alberto Alvarez-Larrán; Carlos Besses; Josep Comín; Silvia de Sanjosé; Eva Domingo-Domenech; Francesc Garcia-Pallarols; Blanca Sánchez-González; Carles Vilaplana; Antonio Salar
NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma.
Leukemia research 2011;35(6):715-20.
2011: Eva Gimeno; Blanca Sánchez-González; Alberto Alvarez-Larrán; Carmen Pedro; Eugenia Abella; Josep Comín; Silvia Saumell; Francesc García-Pallarols; Miquel Gómez; Carles Besses; Antonio Salar
Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma.
Leukemia research 2011;35(3):358-62.
2011: Carles Besses; Alberto Alvarez-Larrán; Luz Martínez-Avilés; Sergi Mojal; Raquel Longarón; Antonio Salar; Lourdes Florensa; Sergi Serrano; Beatriz Bellosillo
Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
British journal of haematology 2011;152(4):413-9.
2011: Juan-Carlos Hernández-Boluda; Alberto Alvarez-Larrán; Montse Gómez; Anna Angona; Paula Amat; Beatriz Bellosillo; Luz Martínez-Avilés; Blanca Navarro; Anabel Teruel; Francisco Martínez-Ruiz; Carles Besses
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.
British journal of haematology 2011;152(1):81-8.
2010: Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán
JAK inhibition in myelofibrosis.
The New England journal of medicine 2010;363(25):2464; author reply 2464-5; discussion 2465.
2010: Francisco Javier Peñalver; Alberto Alvarez-Larrán; Jose Luis Díez-Martin; Laura Gallur; Isidro Jarque; Dolores Caballero; Joaquín Díaz-Mediavilla; Rosalía Bustelos; María Jesús Fernández-Aceñero; José Rafael Cabrera
Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
Annals of hematology 2010;89(11):1073-80.
2010: Alberto Alvarez-Larrán; Francisco Cervantes; Arturo Pereira; Eduardo Arellano-Rodrigo; Virginia Pérez-Andreu; Juan-Carlos Hernández-Boluda; Ramón Ayats; Carlos Salvador; Ana Muntañola; Beatriz Bellosillo; Vicente Vicente; Luis Hernández-Nieto; Carmen Burgaleta; Blanca Xicoy; Carles Besses
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.
Blood 2010;116(8):1205-10; quiz 1387.
2010: Vicent M Guillem; Francisco Cervantes; Jesús Martínez; Alberto Alvarez-Larrán; María Collado; Mireia Camós; Anna Sureda; Margherita Maffioli; Isabel Marugán; Juan-Carlos Hernández-Boluda
XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia.
American journal of hematology 2010;85(7):482-6.
2010: Tiziano Barbui; Alessandra Carobbio; Francisco Cervantes; Alessandro M Vannucchi; Paola Guglielmelli; Elisabetta Antonioli; Alberto Alvarez-Larrán; Alessandro Rambaldi; Guido Finazzi; Giovanni Barosi
Thrombosis in primary myelofibrosis: incidence and risk factors.
Blood 2010;115(4):778-82.
2009: Francisco Cervantes; Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán
Blood cell activation in myeloproliferative neoplasms.
Haematologica 2009;94(11):1484-8.
2009: Alberto Alvarez-Larrán; Julio del Río-Garma; Misericòrdia Pujol; Javier de la Rubia; Manuel Hernández-Jodra; Montserrat Borrell; José R González-Porras; José M García-Gala; Aurora Viejo; Lourdes Enríquez; Cristina Arbona; José A García-Erce; Ana G Noblejas; Arturo Pereira
Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment.
Annals of hematology 2009;88(10):973-8.
2009: Alberto Alvarez-Larrán; Beatriz Bellosillo; Luz Martínez-Avilés; Silvia Saumell; Antonio Salar; Eugenia Abella; Eva Gimeno; Sergi Serrano; Lourdes Florensa; Blanca Sánchez; Carmen Pedro; Carles Besses
Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.
British journal of haematology 2009;146(5):504-9.
2009: Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán; Joan Carles Reverter; Dolors Colomer; Neus Villamor; Beatriz Bellosillo; Francisco Cervantes
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
American journal of hematology 2009;84(2):102-8.
2008: Julio del Río-Garma; Alberto Alvarez-Larrán; Clara Martínez; Josep Muncunill; Dolors Castellà; Javier de la Rubia; Concepción Zamora; Mercedes Corral; Aurora Viejo; Francisco Peña; Pilar Rodríguez-Vicente; Enric Contreras; Cristina Arbona; Consuelo Ramírez; José Antonio Garcia-Erce; Adrián Alegre; José Mateo; Arturo Pereira
Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study.
British journal of haematology 2008;143(1):39-45.
2008: Alberto Alvarez-Larrán; Eduardo Arellano-Rodrigo; Joan Carles Reverter; Abel Domingo; Neus Villamor; Dolors Colomer; Francisco Cervantes
Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis.
Annals of hematology 2008;87(4):269-76.
2007: Luz Martínez-Avilés; Carles Besses; Alberto Alvarez-Larrán; Francisco Cervantes; Juan-Carlos Hernández-Boluda; Beatriz Bellosillo
JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Haematologica 2007;92(12):1717-8.
2007: Alberto Alvarez-Larrán; Francisco Cervantes; Beatriz Bellosillo; M Giralt; A Juliá; Juan-Carlos Hernández-Boluda; A Bosch; L Hernández-Nieto; V Clapés; C Burgaleta; C Salvador; Eduardo Arellano-Rodrigo; Dolors Colomer; Carles Besses
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
Leukemia 2007;21(6):1218-23.
2006: Antonio Salar; Dolors Casao; Marta Cervera; Carmen Pedro; Montserrat Calafell; Eugenia Abella; Alberto Alvarez-Larrán; Carles Besses
Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution.
European journal of haematology 2006;77(4):338-40.
2006: Francisco Cervantes; Alberto Alvarez-Larrán; Juan-Carlos Hernández-Boluda; Anna Sureda; Miquel Granell; Rolando Vallansot; Carles Besses; Emili Montserrat
Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia.
British journal of haematology 2006;134(2):184-6.
2006: Francisco Javier Peñalver; Victor Jiménez-Yuste; Manuel Almagro; Alberto Alvarez-Larrán; Lluis Rodríguez; Marisol Casado; Laura Gallur; Pilar Giraldo; Roberto Hernández; Dolores Menor; Maria José Rodríguez; Dolores Caballero; Raúl González; José Mayans; Isabel Millán; José Rafael Cabrera
Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
Annals of hematology 2006;85(6):400-6.
2006: Eduardo Arellano-Rodrigo; Alberto Alvarez-Larrán; Joan Carles Reverter; Neus Villamor; Dolors Colomer; Francisco Cervantes
Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.
Haematologica 2006;91(2):169-75.
2006: Francisco Cervantes; Alberto Alvarez-Larrán; Eduardo Arellano-Rodrigo; Miquel Granell; A Domingo; Emili Montserrat
Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution.
Leukemia 2006;20(1):55-60.
2005: Alberto Alvarez-Larrán; Juan G Abraldes; Francisco Cervantes; Manuel Hernández-Guerra; Francesco Vizzutti; Rosa Miquel; Rosa Gilabert; Massimo Giusti; Juan Carlos Garcia-Pagan; Jaime Bosch
Portal hypertension secondary to myelofibrosis: a study of three cases.
The American journal of gastroenterology 2005;100(10):2355-8.
2005: Francisco Cervantes; Alberto Alvarez-Larrán; Abel Domingo; Eduardo Arellano-Rodrigo; Emili Montserrat
Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients.
British journal of haematology 2005;129(6):771-5.
2005: Juan-Carlos Hernández-Boluda; Beatriz Bellosillo; Mari-Carmen Vela; Dolors Colomer; Alberto Alvarez-Larrán; Francisco Cervantes
Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients.
Leukemia & lymphoma 2005;46(5):717-22.
2004: Francisco Cervantes; Alberto Alvarez-Larrán; Juan-Carlos Hernández-Boluda; Anna Sureda; Montserrat Torrebadell; Emili Montserrat
Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
British journal of haematology 2004;127(4):399-403.
2004: Alberto Alvarez-Larrán; J Del Río; C Ramírez; C Albo; F Peña; A Campos; J Cid; J Muncunill; J-L Sastre; Cristina Sanz; Arturo Pereira
Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.
Vox sanguinis 2004;86(4):246-51.
2004: Alberto Alvarez-Larrán; Juan Carlos García-Pagán; Juan G Abraldes; Eduardo Arellano; Joan Carles Reverter; Jaime Bosch; Francisco Cervantes
Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera.
British journal of haematology 2004;124(3):329-35.
2003: Francisco Cervantes; Juan-Carlos Hernández-Boluda; Juan Luis Steegmann; Eulogio Conde; Alberto Alvarez-Larrán; Javier López-Jiménez; Santiago Osorio; Lucía Villalón; Mireia Camós; Javier García Conde; Jesús Odriozola
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Haematologica 2003;88(10):1117-22.
2003: Alberto Alvarez-Larrán; Jordi Petriz; Antonio Martínez; Cristina Sanz; Arturo Pereira
Plasma from patients with thrombotic thrombocytopenic purpura induces activation of human monocytes and polymorphonuclear neutrophils.
British journal of haematology 2003;120(1):129-34.
2002: Francisco Cervantes; Alberto Alvarez-Larrán; Carme Talarn; Marta Gómez; Emili Montserrat
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients.
British journal of haematology 2002;118(3):786-90.
2002: Silvia Montoto; Armando López-Guillermo; Ana Ferrer; Mireia Camós; Alberto Alvarez-Larrán; Francesc Bosch; Joan Bladé; Francisco Cervantes; Jordi Esteve; Francesc Cobo; Dolors Colomer; Elias Campo; Emili Montserrat
Survival after progression in patients with follicular lymphoma: analysis of prognostic factors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(4):523-30.
2001: Alberto Alvarez-Larrán; Neus Villamor; Juan-Carlos Hernández-Boluda; Ana Ferrer; Mireia Camós; Elias Campo; Armando López-Guillermo
Blastic natural killer cell leukemia/lymphoma presenting as overt leukemia.
Clinical lymphoma 2001;2(3):178-82; discussion 183-4.
2001: Alberto Alvarez-Larrán; María Rozman; Francisco Cervantes
Simultaneous occurrence of multiple myeloma and chronic myeloid leukemia.
Haematologica 2001;86(8):894.
1999: Alberto Alvarez-Larrán; Armando López-Guillermo; R Miquel; Emili Montserrat
[Subcutaneous panniculitic T-cell lymphoma].
Medicina clínica 1999;113(3):117.